A major resource for this effort is the Applied Gene and Cell Therapy Center (AGCTC), which provides infrastructure to accelerate gene and cell therapies toward the clinic, including product development, GMP manufacturing, analytical development, quality control, and regulatory support in new start of the art facility spanning approximately 55,000 square feet. Priority will be given to investigators applying these approaches to brain tumors/CNS malignancies or myeloid malignancies and to programs with a clear path from biological discovery to preclinical and clinical development.